Healthy Volunteers
Conditions
Brief summary
To estimate the bioavailability of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers.
Detailed description
This is a single center, open-label study in healthy males. Subjects will be screened for eligibility within 28 days of dosing. Twelve subjects will receive single doses of the following treatments in a fixed sequence: Treatment A: Intravenous injection of 1.5 mg PTG-300. Treatment B: 40 mg (40 mg/mL) PTG-300 administered subcutaneously. Treatment C: 40 mg (200 mg/mL) PTG-300 administered subcutaneously. Treatment D: 40 mg (40 mg/mL) PTG-300 administered intramuscularly. There will be a washout period of at least 7 days between Treatment A and Treatment B and at least 12 days between Treatments B, C, and D. Subjects' safety will be monitored, and blood samples will be collected for pharmacokinetics and pharmacodynamics (serum iron, serum ferritin, serum transferrin, and transferrin saturation \[TSAT\]).
Interventions
DRUGPTG-300
Active drug
Sponsors
Protagonist Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Single group of subjects will sequentially receive PTG-300 as IV, subcutaneous, and intramuscular administration
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male volunteers, age 18 to 65 years, inclusive. 2. Subjects must have a Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive. 3. Subjects must have clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator. 4. Agree to use a barrier method of contraception from Day -2 to 90 days after the last dose of study drug. 5. Subjects must have the ability and willingness to attend the necessary visits to the study center.
Exclusion criteria
1. History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, haematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases. 2. History of malignancy, with the exception of adequately treated non-melanomatous skin carcinoma. 3. Mentally or legally incapacitated, has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder that would impact the subjects ability to participate in the trial according to the Investigator. 4. Fever (body temperature \>38°C) or symptomatic viral or bacterial infection within 2 weeks prior to screening; evidence of intestinal infection within 30 days prior to screening. 5. History of severe allergic or anaphylactic reactions. 6. A supine blood pressure outside the range of 90 to 139 mm Hg systolic and 50 to 89 mm Hg diastolic, OR heart rate (HR) \>100 beats per minute at Screening and at Day -1. 7. Laboratory values that are outside the normal range and considered clinically significant by the Investigator. 8. Positive test for hepatitis C antibody, hepatitis B surface antigen or human immunodeficiency virus (HIV) antibody at Screening. 9. Subjects considered at high risk of iron deficiency according to the Investigator. 10. Subjects with iron deficiency as defined by a ferritin or transferrin saturation below the normal range 11. Clinically significant abnormality on ECG performed at the Screening Visit or prior to administration of the initial dose of study drug. 12. Corrected QT (QTcF) greater than 450 msec at Screening. 13. Subjects with a positive toxicology screening panel. 14. Subjects with a history of substance abuse or dependency or history of recreational IV drug use (by self-declaration). 15. Consumption of \>14 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine). 16. Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal remedies (such as St. John's Wort \[Hypericum perforatum\]), beginning 14 days (or 5 half lives, whichever is longer) before administration of the initial dose of study drug and continuing throughout the study until the final study visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bioavailability of PTG-300 | Week 1 | Bioavailability (area under the plasma-concentration time) of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Iron Pharmacodynamics of PTG-300 | Week 1 | Change from baseline in serum iron following subcutaneous and intramuscular administration in healthy volunteers |
| TSAT Pharmacodynamics of PTG-300 | Week 1 | Change from baseline in transferrin saturation (TSAT) following subcutaneous and intramuscular administration in healthy volunteers |
Countries
Australia
Outcome results
None listed